Want to see GNGBY full AI Analyst Report?
GNGBY Stock Chart & Stats
$22.97
$0.02(0.10%)
At close: 4:00 PM EST
$22.97
$0.02(0.10%)
Day’s Range― - ―
52-Week Range$19.29 - $24.82
Previous CloseN/A
Volume7.12K
Average Volume (3M)149.00
Market Cap
$6.54B
Enterprise Value$6.52K
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$11.10B
Price to Earnings (P/E)26.8
Beta0.66
Next Earnings
Oct 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.2%
Share Statistics
EPS (TTM)9.83
Shares Outstanding254,152,370
10 Day Avg. Volume133
30 Day Avg. Volume149
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.02
Price to Sales (P/S)1.70
P/FCF Ratio23.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue MixA large installed base with two-thirds recurring revenue and ~70% high-margin product mix creates durable cash flow and margin resilience. This reduces revenue cyclicality, supports predictable service and consumables sales, and underpins long-term profitability and reinvestment capacity.
Cash GenerationMaterial improvement in operating and free cash flow with strong FCF conversion indicates high earnings quality and internal funding capacity. This strengthens funding for R&D, M&A, dividends and debt servicing, lowering reliance on external financing over the medium term.
Product & M&A Strengthening Recurring BaseTargeted product launches and the Pennamed acquisition expand the consumables and serviceable installed base, lifting recurring revenue potential and cross-sell opportunities. Strategic M&A and new offerings materially reinforce long-term revenue durability and margin mix.
Bears Say
Rising Absolute Debt TrendAn increase in absolute debt, driven by acquisitions, earn-outs and dividends, reduces financial flexibility if conditions weaken. While current leverage is moderate, higher debt increases interest and refinancing risk and constrains capital allocation in adverse scenarios.
Margin Volatility Vs Prior PeaksAlthough margins have rebounded, they remain below earlier peak years and have shown volatility. Sustaining target margins will require consistent mix shift to high-margin disposables, pricing and productivity; any reversal in these drivers or tariff/headwind shocks could compress profits.
Regional & Segment HeadwindsPersistent weakness in APAC/China and the WIS life-science subsegment signals structural demand headwinds in key markets. Prolonged regional softness and competitive pressure in Surgical Workflows can limit revenue growth and delay margin recovery from higher-margin product mix shifts.
Getinge AB News
GNGBY FAQ
What was Getinge AB’s price range in the past 12 months?
Getinge AB lowest stock price was $19.29 and its highest was $24.82 in the past 12 months.
What is Getinge AB’s market cap?
Getinge AB’s market cap is $6.54B.
When is Getinge AB’s upcoming earnings report date?
Getinge AB’s upcoming earnings report date is Oct 20, 2026 which is in 90 days.
How were Getinge AB’s earnings last quarter?
Getinge AB released its earnings results on Jul 17, 2026. The company reported $0.33 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Getinge AB overvalued?
According to Wall Street analysts Getinge AB’s price is currently Overvalued.
Does Getinge AB pay dividends?
Getinge AB pays a Annually dividend of $0.512 which represents an annual dividend yield of 2.2%. See more information on Getinge AB dividends here
What is Getinge AB’s EPS estimate?
Getinge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Getinge AB have?
Getinge AB has 254,152,370 shares outstanding.
What happened to Getinge AB’s price movement after its last earnings report?
Getinge AB reported an EPS of $0.33 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.081%.
Which hedge fund is a major shareholder of Getinge AB?
Currently, no hedge funds are holding shares in GNGBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Getinge AB Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.55%
12-Months-Change
Fundamentals
Return on Equity
2.20%
Trailing 12-Months
Asset Growth
1.50%
Trailing 12-Months
Company Description
Getinge AB
Getinge AB (publ) is a prominent global medical technology provider, delivering comprehensive products and solutions primarily to operating rooms, intensive care units, and sterilization departments. The company operates through three distinct segments: Acute Care Therapies, Life Science, and Surgical Workflows. Its extensive product portfolio for sterile environments includes advanced transfer systems, closure processing systems, washers, isolators, sterilizers, and automated logistic solutions. For the life sciences sector, Getinge offers bioreactors, bioprocess control systems, software, biobundles, analytics, and perfusion systems. Within acute care and surgical settings, offerings span anesthesia machines, patient monitoring systems and disposables, and specialized cardiac surgery tools like beating heart stabilizers and coronary shunts. This segment also provides ceiling supply units, integrated digital solutions, and various cleaning, disinfection, packaging, and sealing products, including its SteriTec range. Further extending its medical device offerings, Getinge supplies a wide array of specialized items such as thoracic catheters, diverse chest drain systems, and related accessories. The portfolio also covers endoscope reprocessing, endoscopic vessel harvesting, endovascular products, and critical extracorporeal life support (ECMO) and intra-aortic balloon pump therapies. Additional provisions include mechanical ventilation, medical furniture, modular room systems, state-of-the-art operating lights and tables, comprehensive OR integration and management solutions, patient flow management systems, and solutions for patient transport, sterile supply management, surgical assist, and surgical perfusion, alongside vascular and cardiothoracic surgery solutions. Getinge distributes its products and solutions globally through a robust network that includes proprietary sales companies, agents, and distributors. This network spans the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. Founded in 1904, Getinge AB (publ) maintains its corporate headquarters in Gothenburg, Sweden.
Technical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors